Issue Date: June 25, 2012
Drug Conjugates Link Merck And Ambrx
Merck & Co. and Ambrx will collaborate on the design and development of antibody-drug conjugates based on Ambrx’ site-specific conjugation technology. San Diego-based Ambrx is one of several biotech firms with technology to control where small-molecule cytotoxins can be attached to tumor-targeting antibodies (C&EN, June 18, page 12). Ambrx will receive an up-front payment of $15 million and is eligible for milestone payments of up to $288 million.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society